about
Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-upEffectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study.The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 studyDrug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community-acquired pneumonia.Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke.Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or olderComparison of three predictive rules for assessing severity in elderly patients with CAP.Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniquesAdvances in pneumococcal vaccines: what are the advantages for the elderly?Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia.Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview.Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.Invasive pneumococcal disease in Catalonian elderly people, 2002-2009: serotype coverage for different anti-pneumococcal vaccine formulations at the beginning of the new conjugate vaccines era.[Estimates of Target Population for Pneumococcal Vaccination in People over 50 years in Catalonia and Spain].Incidence and risk conditions of ischemic stroke in older adults.[Incidence and clinical characteristics of community-acquired pneumonia managed as outpatient among elderly people in Tarragona-Valls, Spain].Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults.Epidemiology of Streptococcus pneumoniae causing acute otitis media among children in Southern Catalonia throughout 2007-2013: Incidence, serotype distribution and vaccine's effectiveness.[Incidence and mortality of ischaemic stroke among people 60 years or older in the region of Tarragona, Spain].Pneumococcal pneumonia in adults 60 years or older: Incidence, mortality and prevention.[Prevalence of serotypes causing invasive pneumococcal disease in the region of Tarragona, Spain, 2006-2009: vaccine-serotype coverage for the distinct antipneumococcal vaccine formulations].[Incidence and lethality of invasive pneumococcal disease in Tarragona, Spain, 2006-2009].Validation of the CORB75 (confusion, oxygen saturation, respiratory rate, blood pressure, and age ≥ 75 years) as a simpler pneumonia severity rule.[Ability of the modified CRB75 severity scale in assessing elderly patients with community acquired pneumonia].Methodology of observational studies of pneumococcal polysaccharide vaccine.Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.[Influenza vaccination and mortality in the elderly].Evaluating the clinical effectiveness of pneumococcal vaccination in preventing myocardial infarction: The CAPAMIS study, three-year follow-up.Effects of annual influenza vaccination on winter mortality in elderly people with chronic pulmonary disease.Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study.[EVAN-65 project: evaluation of the effectiveness of pneumococcus vaccination in the elderly population over 65].Effect of influenza vaccine status on winter mortality in Spanish community-dwelling elderly people during 2002-2005 influenza periods.Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease.[Incidence of pneumococcal pneumonia: the bias of information source].[Pneumococcal vaccination in the over-65 population].Ineffectiveness of pneumococcal vaccination in cardiovascular prevention: the CAPAMIS study.Enfermedad neumocócica en el adulto: niveles de riesgo y recomendaciones de vacunaciónPneumococcal conjugate vaccination: correlates of protectionIncidence of pneumococcal infections among children under 15 years in southern Catalonia throughout the heptavalent conjugate vaccine era, 2002–2009Incidence of invasive pneumococcal disease among elderly people in Southern Catalonia, Spain, 2002–2009: An increase in serotypes not contained in the heptavalent conjugate vaccine
P50
Q33257893-0958802F-E9D5-4087-942C-70781FF7FE57Q33324037-4476B1C2-7B31-4B65-843E-E426DAFED53CQ33347005-92242360-A166-42C1-BA71-698DD16817C4Q33422133-B9435C3F-8C67-4651-9068-4BFB0913321EQ33525198-3DA17A37-3786-4947-A33E-A1805D60733AQ33542866-DBBCD1F0-46C0-478B-BE26-6D6D7A76FAE2Q34032698-9225F679-4DC3-48E5-95F2-2CC9561401A4Q34658291-FBFBD149-41B2-4783-9F1A-85CB05527FA6Q36951922-81681E0A-34DB-4350-9C17-D1A92F2CBE4DQ37473251-98E64A37-9740-44C0-8D50-5E5EFD9B1741Q37981768-C527750E-46D2-4143-B914-4B1B552EAB23Q38082673-A96A9170-5760-4BD7-B562-A68321EE464CQ39722841-CEF8F478-CA55-4F59-A08C-C42E732C8B1DQ40289582-E89C7A17-119D-41F0-80FC-964F8C4D339CQ40291630-F269AAAE-D95C-4392-BE9B-5AC0BFC72E44Q40384108-57B31471-61F1-4880-9E98-8B49E0DDDE24Q40875908-7CA3DFE6-E673-4B82-A7E7-9D6875B6E9A5Q40959203-75B240E4-A69C-45EE-9AE9-888D62F7530CQ40965210-A1A57307-194C-45D3-80FE-A089845AC33FQ41061796-900938B5-1A56-4E66-9451-604FF0AA6815Q41478461-D595E628-FD93-4199-8731-CE93F12AF8D8Q41526767-FD8FE59A-C6AD-427E-A3C8-C3F623B3FAA1Q43487112-F7D1A05E-D42E-4A84-B9BF-AB250687D22BQ43839344-053D5931-54ED-46D9-9E94-B3C6E619E9CEQ43965005-507F1970-9759-4D4D-893C-ADBD9D1279C9Q44532649-35BD0481-A1F3-4923-AF8A-C25D87F6D648Q44781316-0DB6B3A1-D5BE-4A56-B26F-F7C686D6CD8BQ45173223-CE2CD1D3-1B6C-4BF3-AB1F-15F71AF6BEE4Q46971609-E5232D97-D819-4F80-8D27-0C485111FF3AQ47707295-9A393051-18CB-4570-8A15-EDDBAA8FAC90Q50739777-ACF163B7-304D-4A9F-BF5F-88A957F8DCFBQ51104765-8BF40565-D798-4F83-AB6F-12144682A594Q51124928-4EA2F391-2547-4C91-ACEA-97BC732E8A04Q52998872-7FAEEFBC-506D-4B90-BA47-292CC5310DCEQ53739979-BF3BE6B1-E845-489E-A830-665B8DA5DCCBQ54494878-6BE2CB96-8544-4D21-83A7-B40658B880C4Q63392507-0A7BF65A-6F8F-4F9D-B9B4-E4684E5BA7C9Q63392515-1F547747-5883-4535-BC6B-E3A1A17192F2Q63392520-EC7D01D0-2351-42D7-9F89-6E04212A77FBQ63392527-F52FF1F9-D015-42CA-AB26-9ECE9FC043B5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Angel Vila-Córcoles
@ast
Angel Vila-Córcoles
@en
Angel Vila-Córcoles
@es
Angel Vila-Córcoles
@nl
Angel Vila-Córcoles
@sl
type
label
Angel Vila-Córcoles
@ast
Angel Vila-Córcoles
@en
Angel Vila-Córcoles
@es
Angel Vila-Córcoles
@nl
Angel Vila-Córcoles
@sl
prefLabel
Angel Vila-Córcoles
@ast
Angel Vila-Córcoles
@en
Angel Vila-Córcoles
@es
Angel Vila-Córcoles
@nl
Angel Vila-Córcoles
@sl
P106
P21
P31
P496
0000-0002-1644-0188